UK Trade Groups Question MHRA’s ‘No-Deal’ Brexit Plan

Drug Industry Daily
Two prominent UK drug organizations say they’re “generally supportive” of MHRA’s contingency plans if the UK exits the EU on March 29 without a deal, but expressed concern about orphan drugs and centrally authorized product licenses, among other issues.

To View This Article:


Subscribe To Drug Industry Daily